privately held medical device firm named Artelon Inc. said today that it had closed a $20 million Series B investment round, led by Vensana Capital with planned participation from additional existing investors. The funding will support Artelon’s product line development for surgically treating ankles and other joints, as well as commercial growth and clinical research.
According to CEO Aaron Smith, “Artelon has focused deeply on surgical solutions for ankle instability, a large and underserved market.” “In the United States, ankle sprains account for the majority of trips to the emergency room, and up to 20% of those individuals will experience persistent instability as a result of their injury. Traditional surgical methods can reduce ankle instability, but patients must recover for a lengthy time and may still experience discomfort or instability in the future. in the long run.” More than 30 years of study and knowledge on the intricate interplay of mechanics and biology in tendon and ligament regeneration go into Artelon’s cutting-edge surgical treatments. This funding will enable us to pursue leadership within the $2 billion U.S. ankle instability market and build on the commercial success of our current Flexband® SOLO and Flexband MULTI products, while extending our efforts to address latent consumer needs in other unstable joints.
According to Greg Banker of Vensana Capital, “Artelon is committed to bringing value to patients and healthcare providers through a platform that enhances soft tissue repair while restoring stability and motion.” “They are on a mission to enable faster healing and higher results for patients, while seamlessly integrating into the existing healthcare system. clinical workflows.” Added Vensana’s Kirk Nielsen, “Vensana is excited to join the Artelon team and to support their efforts to establish themselves as a technology and market leader.”
Artelon’s Dynamic Matrix® technology is a proprietary polymeric bio-textile for musculoskeletal soft tissue reconstruction. Dynamic Matrix is designed to mimic the natural mechanical and biological properties of healing ligament tissue. It has been proven in clinical studies to protect the surgical repair during early healing, quickly restore the mechanics of motion, and support development of regenerating tissue before dissolving over five to six years.
